Company profile

ChromoLogic

chromologic.comHeadquarters: United States
11-50 employeesHybrid (Product + Service)
ChromoLogic logo

Primary focus

Applied research and commercialization of technologies for medical, aerospace, and security markets, with a focus on point-of-care biomedical devices, diagnostics, drug-delivery platforms, optical instrumentation, neuromorphic software, and supply-chain traceability.

Why it’s included

The company develops and manufactures 'Quick-MAG,' a low-cost rugged magneto-optical sensing system for highly-sensitive malaria screening, explicitly addressing field-suitable rapid diagnostics for malaria in resource-limited settings and low-parasitemia contexts.

Relevant capabilities

  • Magneto-optical detection for parasitemia and hemozoin measurement
  • Nucleic acid diagnostics and point-of-care assay development
  • Microbial genome enrichment and low-biomass sequencing workflows
  • In‑line, non‑invasive optical cell monitoring (OCT-based)
  • Optical coherence tomography for structural and biomechanical measurements
Commercial sectorUltrasensitive and Reader-Assisted Diagnostic Platforms
Technology classesCRISPR-based nucleic acid detection

Relevant commercial products

  • Quick-MAG
  • QuickMag
  • CAPTIN-D
  • Point-of-care nucleic acid diagnostic workflows
  • PANACIA™

Relevant patents

4 families, 5 publications

← Back to what’s inside this report